Model for end stage liver disease meld score Assessment Tool — Free hepatology Risk Score Calculator

How it Works

The 4 Core Variables

Creatinine (mg/dL): The primary marker of renal function. Renal failure is a devastating complication of cirrhosis (Hepatorenal Syndrome).

Bilirubin (mg/dL): The primary marker of the liver's ability to excrete waste products and handle cholestasis.

INR (Ratio): The primary marker of the liver's synthetic capacity, specifically the production of clotting factors.

Sodium (mEq/L): A surrogate marker for portal hypertension and the hemodynamic state of the patient.

The Scoring Formula

The score is a complex logarithmic function. The base MELD is calculated first. If the base MELD is > 11, the sodium correction is applied using the following logic: MELD-Na = MELD - Sodium - [0.025 × MELD × (140 - Sodium)] + 12. Sodium levels are capped at 125 and 137 mEq/L for the calculation.

Caps and Minimums

Lower limit for labs: 1.0 mg/dL (to avoid negative logs).

Max Creatinine: 4.0 mg/dL.

Max MELD-Na: 40 (Patients with higher scores are prioritized equally at the top of the list).

Mortality Estimates

Score ≥ 40	71.3% 90-day mortality
Score 30–39	52.6% 90-day mortality
Score 20–29	19.6% 90-day mortality
Score 10–19	6.0% 90-day mortality
Score < 10	1.9% 90-day mortality

Clinical Pearls

Creatinine Capping & Dialysis

Creatinine is capped at 4.0 mg/dL. Patients who have received at least two dialysis treatments within the prior 7 days, or 24 hours of continuous veno-venous hemodialysis (CVVHD), automatically receive a creatinine value of 4.0 mg/dL for the calculation.

MELD Exceptions

Some conditions carry a higher risk of death than the MELD score reflects. Common "Exception Points" are granted for: Hepatocellular Carcinoma (within Milan criteria), Hepatopulmonary Syndrome, Portopulmonary Hypertension, and Familial Amyloid Polyneuropathy.

Female Disadvantage & MELD 3.0

Because women generally have less muscle mass, their serum creatinine levels are often lower than men's for the same degree of GFR impairment. This leads to lower MELD scores and longer wait times. The new MELD 3.0 (2024) includes a sex-based correction and albumin to fix this inequity.

The "MELD Jump"

A rapid increase in MELD (e.g., >3 points in a month) is often more clinically significant than a high but stable score. It usually indicates an acute hit such as SBP, portal vein thrombosis, or alcoholic hepatitis flare.

Next Steps

MELD-Based Triage and Monitoring

MELD ≥ 15: Formal liver transplant evaluation is mandatory (The "Share 15" rule).

MELD ≥ 25: Requires lab updates every 7 days to maintain waitlist position.

MELD 19–24: Requires lab updates every 30 days.

MELD 11–18: Requires lab updates every 90 days.

Surgical Risk Assessment

Patients with a MELD > 15 undergoing non-transplant surgery have significantly increased perioperative mortality. Avoid elective surgery in these patients until transplant evaluation is complete.

Refractory Ascites

Evaluate for TIPS (Transjugular Intrahepatic Portosystemic Shunt) if MELD is < 18. TIPS in patients with MELD > 18 is associated with high rates of post-procedure liver failure and death.

The Evidence

Foundational Studies

A model to predict survival in patients with end-stage liver disease.

Kamath PS et al. • Hepatology. 2001;The original validation of MELD using a cohort of patients undergoing TIPS. It proved that a simple mathematical model could outperform the Child-Pugh score.

Hyponatremia and mortality among patients on the liver-transplant waiting list.

Kim WR et al. • N Engl J Med. 2008;Proved that serum sodium was a potent independent predictor of mortality, leading to the development of the MELD-Na formula.

Global Validation and Updates

Model for end-stage liver disease (MELD) and allocation of donor livers.

Wiesner R et al. • Gastroenterology. 2003;The study that validated MELD for use in the US national transplant allocation system.

MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.

Kim WR et al. • Gastroenterology. 2021;The paper describing the refined MELD 3.0 formula, which includes sex-based adjustments and albumin.

Additional References

Biggins SW, et al. Evidence-based incorporate of serum sodium in MELD. Gastroenterology. 2006.

Malinchoc M, et al. A model to predict poor survival in liver cirrhosis. Hepatology. 2000.

Heuman DM, et al. MELD and prediction of post-transplant survival. Liver Transpl. 2003.

Merion RM, et al. Comparison of liver transplant survival benefit by MELD score. JAMA. 2005.

Origins & History

The Mayo Clinic Breakthrough

The MELD score was originally developed at the Mayo Clinic in Rochester, Minnesota. It was not intended for transplant, but rather to predict the survival of patients undergoing the TIPS procedure. The researchers (Kamath, Malinchoc, et al.) realized the formula's potential for broader use.

The UNOS Revolution (2002)

Before 2002, liver allocation was based on Child-Pugh and "time on the list." This led to "gaming" of the system and high waitlist mortality. UNOS (United Network for Organ Sharing) adopted MELD on February 27, 2002, creating a purely data-driven system that prioritized medical urgency over wait time.

Continuous Refinement

The history of MELD is one of constant evolution. From the "Original MELD" (2002) to "MELD-Na" (2016) and now "MELD 3.0" (2024), each iteration has sought to fix inequities and improve the accuracy of survival prediction in the ever-changing landscape of end-stage liver disease.

Model for End-Stage Liver Disease (MELD Score)

Clinical Significance

Transplant Allocation Standard

The Sodium (Na) Factor

Predicting 90-Day Mortality

Global Adoption

How it Works

The 4 Core Variables

The Scoring Formula

Caps and Minimums

Mortality Estimates

Clinical Pearls

Creatinine Capping & Dialysis

MELD Exceptions

Female Disadvantage & MELD 3.0

The "MELD Jump"

Next Steps

MELD-Based Triage and Monitoring

Surgical Risk Assessment

Refractory Ascites

The Evidence

Foundational Studies

A model to predict survival in patients with end-stage liver disease.

Hyponatremia and mortality among patients on the liver-transplant waiting list.

Global Validation and Updates

Model for end-stage liver disease (MELD) and allocation of donor livers.

MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.

Additional References

Origins & History

The Mayo Clinic Breakthrough

The UNOS Revolution (2002)

Continuous Refinement

Related Tools

In Recent Clinical News

Model for End-Stage Liver Disease (MELD Score)

Clinical Significance

Transplant Allocation Standard

The Sodium (Na) Factor

Predicting 90-Day Mortality

Global Adoption

How it Works

The 4 Core Variables

The Scoring Formula

Caps and Minimums

Mortality Estimates

Clinical Pearls

Creatinine Capping & Dialysis

MELD Exceptions

Female Disadvantage & MELD 3.0

The "MELD Jump"

Next Steps

MELD-Based Triage and Monitoring

Surgical Risk Assessment

Refractory Ascites

The Evidence

Foundational Studies

A model to predict survival in patients with end-stage liver disease.

Hyponatremia and mortality among patients on the liver-transplant waiting list.

Global Validation and Updates

Model for end-stage liver disease (MELD) and allocation of donor livers.

MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.

Additional References

Origins & History

The Mayo Clinic Breakthrough

The UNOS Revolution (2002)

Continuous Refinement

Related Tools

In Recent Clinical News